December 15, 2023
Insights from the IPOPI Latin American PID Patients Meeting 2023
The vibrant city of Mexico City served as the host to the IPOPI Latin American PID Patients Meeting on October 19-20, 2023, held in parallel with the Latin American Society for Primary Immunodeficiencies (LASID) meeting. The two-day program was thoughtfully tailored to address the pressing challenges and opportunities faced by the region.
A total of 35 participants from 12 Latin American countries, including Argentina, Bolivia, Brazil, Chile, Costa Rica, Ecuador, El Salvador, Mexico, Paraguay, Peru, Puerto Rico, and Uruguay, gathered to share experiences and insights.
A key focus was a session dedicated to navigating the regulatory processes, on immunoglobulin approval, countering counter-fake medicines, and pharmaceutical co-vigilance. This session provided valuable insights into ensuring the safety and authenticity of medical treatments. Participants sharpened their advocacy skills, for enhanced treatment access and plasma collection. Topics included strategies for future endemics, PID diagnosis, treatment, care, participation in an interactive transition care panel, and engaging in a workshop.
A highlight of the meeting was the opportunity to hear from various national member organisations (NMOs) about their latest impactful projects in their respective countries. This exchange allowed participants to learn from each other’s successes and innovations, fostering inspiration and collaboration.
In conclusion, the IPOPI Latin American PID Patients Meeting has fostered a joint commitment to ongoing collaboration in addressing regional challenges, marking a step forward for those affected by primary immunodeficiencies in Latin America.
IPOPI would like to thank LASID and IPOPI’s Mexican member organisation, AMPIP, for their collaboration and support in organising this meeting.
Stay tuned for the meeting report that will capture the insightful discussions and key takeaways, a valuable resource for advancing PID healthcare in the region.
This meeting was made possible thanks to the support from Grifols and Takeda.
